Objective:To investigate the expression and clinical significance of glycosylated albumin(GA) and glycosylated hemoglobin(HbA1c) in patients with diabetic microangiopathy(MVCD).Methods:A total of 295 patients with type 2 diabetes admitted to Chaoyang Central Hospital of Liaoning Province from May 2017 to July 2019 were selected as case group, and they were divided into simple diabetes group (217) and microvascular disease group (78) according to whether the patients had microvascular lesions.Two hundred healthy people were selected as normal control group.The levels of GA and HbA1c were compared between the case group and the normal control group, and the levels of GA and HbA1c in the diabetic group and the microvascular disease group were compared.The risk factors of microangiopathy in patients with type 2 diabetes mellitus were analyzed by logistic regression analysis.Results:The levels of GA and HbA1c were (23.9±10.1)% and (8.6±2.3)% in the case group, which were (13.4±1.2)% and (5.0±0.6)% in the normal control group.The differences between the two groups were statistically significant( t=14.628, 21.636, all P<0.01). The levels of GA and HbA1c were (22.8±9.7)% and (8.4±2.0)% in the simple diabetes group and (25.4±10.3)% and (9.2±2.4)% in the microvascular disease group.The differences between the two groups were statistically significant( t=1.997, 2.869, P=0.047, 0.004). Logistic regression analysis showed that GA and HbAlc were risk factors for microangiopathy in patients with type 2 diabetes ( OR (95% CI) values were 1.088 (1.030-1.157) and 15.251 (1.756-131.157), P=0.003 and 0.014). Conclusion:The occurrence of MVCD is related to GA and HbA1c.Logistic regression analysis showed that GA and HbA1c levels were risk factors of MVCD, and could be used as predictive factors of MVCD.

Objective To isolate and identify side population (SP) cells like cancer stem cell from human pancreatic cancer cell line SW1990, for the purpose of further evaluation of their biological characteristics. Methods Cell suspension was stained with Hoechst 33342 and PI. Then SP cells were analyzed in the fluorescence activated cell sorter. Cell growth viability was measured by MTT. Stem cell marker CD133 was determined by flow cytometry. Cloning forming efficiency was determined by cloning plating. Expression of ABCG2 protein was detected by Western blot analysis. Results The proportion of SP cells was 2.7%, however it could be completely blocked by verapamil. 9 days later, the value of A492 of SP cells was 2.1, the cloning forming efficiency was (38.7 ± 6.8) % , the positive rate of CD133 was 69.63%, which were significantly higher than cells 0. 5, ( 15.5 ± 2.8)%, 16.71% of corresponding non-SP( P <0.05). The expression of ABCG2 in SP cells was significantly higher than that in non-SP cells. Conclusions SP cells existed in human pancreatic cancer cells SW1990.

Objective:To investigate the relationship and clinical significance between serum 25(OH)D level and diabetic microangiopathy.Methods:The clinical data of 198 patients in Chaoyang Central Hospital with Type 2 diabetes from October 2018 to October 2019 were analyzed retrospectively.Patients were divided into simple diabetes group (50 cases) and microangiopathy group (148 cases) according to whether the patients had microvascular disease or not.The concentration of serum 25(OH)D in two groups of diabetic patients was compared and analyzed.Patients with type 2 diabetes were divided into two groups, which was 25 (OH)D <50 nmol/L Group (121 cases) and 25 (OH)D ≥50 nmol/L Group (77 cases) according to the different serum concentrations of 25 (OH)D.The incidence of MVCD was analyzed and compared between the two groups.The risk factors of MVCD were analyzed by Logistic regression analysis.Results:Compared with the simple diabetes group, the serum 25(OH)D levels in patients with microangiopathy were significantly lower((44.1±19.0) nmol/L vs.(50.9±20.1) nmol/L). The differences between the two groups were statistically significant ( t=2.156, P<0.05). The incidence of diabetic retinopathy, diabetic nephropathy and peripheral neuropathy in 25 (OH)D<50 nmol/L Group were 37.2%(45/121), 43.0%(52/121), 54.5%(66/121), and those in 25 (OH)D≥50 nmol/L Group were 20.8%(16/77), 16.9%(13/77), 32.5%(25/77). The differences between the two groups were statistically significant (χ 2 values were 5.950, 14.530, 9.231, all P<0.05). Logistic Regression analysis showed that 25(OH)D was a protective factor for MVCD ( OR(95% CI): 1.081(1.030-1.197), P=0.003). Conclusion:The incidence of MVCD is related to the level of Serum 25(OH)D, and serum 25(OH)D is the protective factor of MVCD.